Works matching AU Lu, Yen-Shen


Results: 64
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13

    Anti-tumor efficacy of a bevacizumab preconditioning followed by etoposide and cisplatin regimen in human epidermal growth factor receptor-2-positive breast cancer brain metastasis refractory to whole brain radiotherapy.

    Published in:
    Journal of Cancer Research & Practice, 2023, v. 10, n. 1, p. 11, doi. 10.4103/ejcrp.eJCRP-D-23-00001
    By:
    • Chen, Tom;
    • Lin, Ching-Hung;
    • Yeh, Dah-Cherng;
    • Tseng, Ling-Ming;
    • Rau, Kun-Ming;
    • Chen, Bang-Bin;
    • Chao, Ta-Chung;
    • Huang, Shu-Min;
    • Chang, Dwan-Ying;
    • Chen, I-Chun;
    • Cheng, Ann-Lii;
    • Lu, Yen-Shen
    Publication type:
    Article
    14

    Response to Sung, Rosenberg, and Yang.

    Published in:
    2020
    By:
    • Lin, Ching-hung;
    • Yap, Yoon sim;
    • Lee, Kyung-hun;
    • Yeo, Winnie;
    • Ueno, Takayuki;
    • Li, Huiping;
    • Huang, Shu-min;
    • Lu, Yen-shen
    Publication type:
    Letter
    15
    16
    17
    18
    19
    20

    A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer.

    Published in:
    NPJ Breast Cancer, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41523-024-00684-w
    By:
    • Noguchi, Emi;
    • Yamanaka, Takashi;
    • Mukai, Hirofumi;
    • Yamamoto, Naohito;
    • Chung, Chi-Feng;
    • Lu, Yen-Shen;
    • Chang, Dwan-Ying;
    • Sohn, Joohyuk;
    • Kim, Gun Min;
    • Lee, Kyung-Hun;
    • Lee, Soo-Chin;
    • Iwasa, Tsutomu;
    • Iwata, Hiroji;
    • Watanabe, Kenichi;
    • Jung, Kyung Hae;
    • Tanabe, Yuko;
    • Kang, Seok Yun;
    • Yasojima, Hiroyuki;
    • Aogi, Kenjiro;
    • Tokunaga, Eriko
    Publication type:
    Article
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39

    Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐positive early breast cancer: A meta‐regression analysis.

    Published in:
    Cancer Medicine, 2024, v. 13, n. 14, p. 1, doi. 10.1002/cam4.70005
    By:
    • Yang, Ming‐Han;
    • Huang, Chiun‐Sheng;
    • Chang, Dwan‐Ying;
    • Hu, Fu‐Chang;
    • Huang, Shu‐Min;
    • Huang, Po‐Hsiang;
    • Chen, I‐Chun;
    • Chen, Tom Wei‐Wu;
    • Lin, Ching‐Hung;
    • Lu, Yen‐Shen
    Publication type:
    Article
    40
    41

    Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.

    Published in:
    Nature Communications, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41467-025-59210-6
    By:
    • Hu, Xichun;
    • Zhang, Qingyuan;
    • Sun, Tao;
    • Xiong, Huihua;
    • Li, Wei;
    • Teng, Yuee;
    • Lu, Yen-Shen;
    • Tseng, Ling-Ming;
    • Yan, Min;
    • Li, Hongsheng;
    • Pang, Danmei;
    • -Chen, Shin-Cheh;
    • Chen, Wenyan;
    • Jiang, Ou;
    • Wang, Jingfen;
    • Wu, Xinhong;
    • Wang, Xian;
    • Zang, Aimin;
    • Wang, Xiaojia;
    • Collins, Julie M.
    Publication type:
    Article
    42
    43
    44
    45
    46
    47
    48
    49
    50

    Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7).

    Published in:
    Therapeutic Advances in Medical Oncology, 2020, v. 12, p. 1, doi. 10.1177/1758835920943065
    By:
    • Harbeck, Nadia;
    • Franke, Fabio;
    • Villanueva-Vazquez, Rafael;
    • Lu, Yen-Shen;
    • Tripathy, Debu;
    • Chow, Louis;
    • Babu, Govind K;
    • Im, Young-Hyuck;
    • Chandiwana, David;
    • Gaur, Anil;
    • Lanoue, Brad;
    • Rodriguez-Lorenc, Karen;
    • Bardia, Aditya
    Publication type:
    Article